Activities of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis

@article{Bogdanovich2006ActivitiesOC,
  title={Activities of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis},
  author={T. Bogdanovich and C. Clark and L. Ednie and G. Lin and Kathy Smith and S. Shapiro and P. Appelbaum},
  journal={Antimicrobial Agents and Chemotherapy},
  year={2006},
  volume={50},
  pages={2050 - 2057}
}
ABSTRACT Ceftobiprole, a broad-spectrum pyrrolidinone-3-ylidenemethyl cephem currently in phase III clinical trials, had MICs between 0.008 μg/ml and 8.0 μg/ml for 321 clinical isolates of Haemophilus influenzae and between ≤0.004 μg/ml and 1.0 μg/ml for 49 clinical isolates of Moraxella catarrhalis. Ceftobiprole MIC50 and MIC90 values for H. influenzae were 0.06 μg/ml and 0.25 μg/ml for β-lactamase-positive strains (n = 262), 0.03 μg/ml and 0.25 μg/ml for β-lactamase-negative strains (n = 40… Expand
Multistep Resistance Development Studies of Ceftaroline in Gram-Positive and -Negative Bacteria
TLDR
The potential for ceftaroline and comparator antibiotics to select for clones of Streptococcus pneumoniae, StrePTococcus pyogenes, Haemophilus influenzae, Moraxella catarrhalis, Klebsiella pneumoniaes, Staphylococcus aureus, and Enterococcus faecalis with elevated MICs was evaluated. Expand
Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin.
TLDR
Ceftobiprole was less active against beta-lactamase-positive Gram-negative bacilli, especially the members of the Bacteroides fragilis group, and piperacillin was active mainly against beta/lactAMase-negative strains, though MIC values for p Piperacillin were often 1 to 2 dilutions higher than for ceftob Piprole. Expand
Time-Kill and Synergism Studies of Ceftobiprole against Enterococcus faecalis, Including β-Lactamase-Producing and Vancomycin-Resistant Isolates
TLDR
Ceftobiprole exhibited good in vitro activity against E. faecalis, including Bla+ and vancomycin-resistant strains, and exhibited synergism with aminoglycosides against selected isolates. Expand
Ceftobiprole: a new broad spectrum cephalosporin
TLDR
Ceftobiprole was well tolerated with a safety profile consistent with the cephalosporin class of antibiotic, and the most frequent drug-related adverse event was dysgeusia. Expand
Ceftobiprole: a new broad spectrum cephalosporin.
TLDR
While the drug met the noninferiority criteria for community-acquired pneumonia and nosocomial pneumonia involving non-ventilator associated pneumonia, ceftobiprole was less effect... Expand
Antimicrobial activity of ceftobiprole against gram-negative and gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study.
TLDR
Antimicrobial susceptibility testing against bacterial isolates recently collected from Brazilian private hospitals showed that ceftobiprole has potent activity against staphylococci and E. faecalis, which was superior to that of vancomycin and cefepime and ceftazidime against key gram-negative species. Expand
Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
TLDR
In vitro potency of ceftobiprole is a new anti-MRSA beta-lactam with recognized activity against the most commonly occurring Enterobacteriaceae and P. aeruginosa, similar to that of extended-spectrum cephems, and warrant continued evaluation of the agent as empiric therapy for cSSSIs, and in pneumonia. Expand
Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
TLDR
The efficacy of ceftobiprole was demonstrated in two pivotal studies in patients with complicated skin and skin-structure infections (cSSSIs) and the pharmacokinetic/pharmacodynamic profile supports the use of ceftenbiprole to treat a wide range of c SSSIs. Expand
Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
TLDR
Ceftobiprole, a broad-spectrum cephalosporin with demonstrated in vitro activity against Gram-positive cocci, is a weak inducer and a poor substrate for AmpC beta-lactamases and demonstrates limited activity against anaerobes such as Bacteroides fragilis and non-fragilis. Expand
Ceftobiprole Activity against over 60,000 Clinical Bacterial Pathogens Isolated in Europe, Turkey, and Israel from 2005 to 2010
TLDR
Ceftobiprole demonstrated a wide spectrum of antimicrobial activity against this very large longitudinal sample of contemporary pathogens isolated in Europe, Turkey, and Israel during 2005 through 2010. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 40 REFERENCES
Activities and Postantibiotic Effects of Gemifloxacin Compared to Those of 11 Other Agents againstHaemophilus influenzae and Moraxella catarrhalis
TLDR
The activity of gemifloxacin against Haemophilus influenzae and Moraxella catarrhalis was compared to those of 11 other agents and the postantibiotic effects (PAEs) against four quinolone-susceptible H. Influenzae strains were compared. Expand
Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin
TLDR
Ceftobiprole is a novel cephalosporin with expanded activity against gram-positive bacteria and single-passage selections showed very low frequencies of resistance to ceftoiprole irrespective of genotype or phenotype. Expand
Susceptibilities of Haemophilus influenzae andMoraxella catarrhalis to ABT-773 Compared to Their Susceptibilities to 11 Other Agents
TLDR
ABT-773 and azithromycin gave the longest postantibiotic effects (PAEs) of the ketolide-macrolide-azalide group tested, and β-lactams were bactericidal against 8 to 10 strains at two times the MIC after 24 h, with slower killing at earlier time periods. Expand
Antipneumococcal Activity of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin
TLDR
Prolonged serial passage in the presence of subinhibitory concentrations of ceftobiprole failed to yield mutants with high MICs towards this Staphylococcus aureus cephalosporin, and single-passage selection showed very low frequencies of spontaneous mutants with breakthroughMICs towards ceftOBiprole. Expand
Activities of Two Novel Macrolides, GW 773546 and GW 708408, Compared with Those of Telithromycin, Erythromycin, Azithromycin, and Clarithromycin against Haemophilus influenzae
TLDR
The results of in vitro studies obtained with both novel macrolides were similar to those obtaining with telithromycin and better than those obtained with older macrolide, and Alterations in the L22 protein and the L4 protein were present in mutants selected by the single-step selection process. Expand
Activity of HMR 3647 Compared to Those of Five Agents againstHaemophilus influenzae and Moraxella catarrhalisby MIC Determination and Time-Kill Assay
TLDR
Azithromycin was bactericidal against all 10 H. influenzae and 3 of 5 M. catarrhalis isolates and HMR 3647 were bacteriostatic, against all 15 strains after 24 h at the MIC. Expand
In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.
TLDR
BAL9141 demonstrated excellent activity against many tested pathogens displaying various resistance phenotypes, and should be particularly valuable in the treatment of MRSA as well as for drug-resistant streptococci, while maintaining a spectrum resembling a 'third-generation' cephalosporin against other clinically important species. Expand
Effects of an Efflux Mechanism and Ribosomal Mutations on Macrolide Susceptibility of Haemophilus influenzae Clinical Isolates
TLDR
It is concluded that the vast majority of H. influenzae strains have a macrolide efflux mechanism, with a few of these being hyperresistant (1.3%) due to one or several ribosomal mutations. Expand
Comparative in-vitro activity of azithromycin and erythromycin against Gram-positive cocci, Haemophilus influenzae and anaerobes.
TLDR
The in-vitro activities of azithromycin and erythromycin were compared against 689 clinical isolates, including Gram-positive cocci, Haemophilus influenzae, and anaerobes, and the anaerobic bacteria tested showed similar susceptibility to both azithrochemical compounds. Expand
In Vitro and In Vivo Properties of Ro 63-9141, a Novel Broad-Spectrum Cephalosporin with Activity against Methicillin-Resistant Staphylococci
TLDR
The potential utility of Ro 63-9141 for the therapy of infections caused by susceptible pathogens, including MRSA, is suggested and a water-soluble prodrug, Ro 65-5788, is considered for development. Expand
...
1
2
3
4
...